AbstractObjectivesThis case report aims to describe the effects of craniosacral therapy and acupuncture in a patient with chronic migraine.
MethodsA 33-year-old man with chronic migraine was treated with 20 sessions of craniosacral therapy and acupuncture for 8 weeks. The number of migraine and headache days were monitored every month. The pain intensity of headache was measured on the visual analog scale (VAS). Korean Headache Impact Test-6 (HIT-6) and Migraine Specific Quality of Life (MSQoL) were also used.
ResultsThe number of headache days per month reduced from 28 to 7 after 8 weeks of treatment and to 3 after 3 months of treatment. The pain intensity of headache based on VAS reduced from 7.5 to 3 after 8 weeks and further to < 1 after 3 months of treatment. Furthermore, the patient’s HIT-6 and MSQoL scores improved during the treatment period, which was maintained or further improved at the 3 month follow-up. No side effects were observed during or after the treatment.
참고문헌1. Arnold M.(2018). Headache classification committee of the International Headache Society (IHS): The international classification of headache disorders. 3rd edition. Cephalalgia. 38:(1. p. 1-211. 10.11770333102417738202
2. An H.K., Do J.K., Park J.Y., Han C.H., & Lee D.K.(2007). Comparisons of life quality between chronic and episodic migraine patients. Journal of the Korean Neurological Association;25(3):293-297.
3. Hovaguimian A., & Roth J.(2022). Management of chronic migraine. British medical journal;379e06767010.1136/bmj-2021-067670
  4. Kwak M.J., Han Y.H., Geum J.H., Park S.H., Woo H.J., Ha W.B., & Lee J.H.(2022). Trends in domestic and international clinical research of craniosacral therapy. Scoping Review Journal of Korean Medicine Rehabilitation;32(3):13-27. 10.18325/jkmr.2022.32.3.13
5. Arnadottir T.S., & Sigurdardottir A.K.(2013). Is craniosacral therapy effective for migraine? Tested with HIT-6 Questionnaire;19(1):11-14. 10.1016/j.ctcp.2012.09.003
6. Haller H., Lauche R., Sundberg T., Dobos G., & Cramer H.(2020). Craniosacral therapy for chronic pain: a systematic review and meta-analysis of randomized controlled trials. BMC Musculoskeletal Disorders;21(1):110.1186/s12891-019-3017-y1471-2474.
7. Upledger J.E., Vrendevoogd J.D.(1983). Craniosacral therapy. 3rd ed. Seattle. Eastland Press.
8. Blumenfeld A.M., Kaur G., Mahajan A., Shukla H., Sommer K., Tung A., & Knievel K.L.(2022). Effectiveness and safety of chronic migraine preventive treatments: A Systematic Literature Review. Pain and Therapy;12(1):251-274. 10.1007/s40122-022-00452-3
 9. Jensen M.P., Chen C., & Brugger A.M.(2003). Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. Journal of Pain;4(7):407-414. 10.1016/s1526-5900(03)00716-8
10. Kosinski M., Bayliss M.S., Bjorner J.B., Ware J.E., Garber W.H., Batenhorst A., Cady R., Dahlöf C.G.H., Dowson A., & Tepper S.(2003). A six-item short-form survey for measuring headache impact: the HIT-6. Quality of life research;12(8):963-974. 10.1023/A:1026119331193
11. Chu M.K., Im H.J., Ju Y.S., Yu K.H., Ma H.I., Kim Y.J., Kim J.Y., & Lee B.C.(2009). Validity and reliability assessment of Korean headache impact test-6 (HIT-6). Journal of the Korean Neurological Association;27(1):1-6.
12. Lipton R.B., Stewart W.F., Sawyer J., & Edmeads J.G.(2001). Clinical utility of an instrument assessing migraine disability:the Migraine Disability Assessment(MIDAS) questionnaire. Headache;41(9):854-861.
13. Khara M.S., Marianne S.R., Werner J.B., Suzanne N.C., Rose G., Gordon F.M., Arnoldas G.E., & Marek J.G.(2010). HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache;50(3):383-395. 10.1111/j.1526-4610.2009
14. Wagner T.H., Patrick D.L., Galer B.S., & Berzon R.A.(1996). A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache;36(8):484-492. 10.1046/j.1526-4610.1996.3608484.x
15. Moon H.S., Chung C.S., Lee H.S., Park H.S., Kim S.W., & Woo H.W.(2003). The reliability and validity of the migraine-specific quality of life questionnaire for Korean migraine suffers. Journal of the Korean Neurological Association;21(2):146-155.
16. Moon H.S.(2018). Comprehensive review and update on chronic migraine. Journal of Korean American Medical Association;61(5):314-322. 10.5124/jkma.2018.61.5.314
17. Ishii R., Schwedt T.J., Dumkrieger G., Lalvani N., Craven A., Goadsby P.J., Lipton R.B., Olesen J., Silberstein S.D., Burish M.J., & Dodick D.W.(2021). Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache;61(7):992-1003. 10.1111/head.14154
18. Sauro K.M., Rose M.S., Becker W.J., Christie S.N., Giammarco R., Mackie G.F., Eloff A.G., & Gawel M.J.(2010). HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache;50(3):383-395. 10.1111/j.1526-4610.2009.01544.x
19. Zhang N., Houle T., Hindiyeh N., & Aurora S.K.(2020). Systematic review: acupuncture vs standard pharmacological therapy for migraine prevention. Headache;60(2):309-317. 10.1111/head.13723
20. Lee S.J., Lee S.H., Heo I., Hwang E.H., Lim H.H., & Song Y.K.(2020). Chuna craniosacral therapy for headache: a systematic review and meta analysis. The Journal of Korea CHUNA Manual Medicine for Spine & Nerves;15(1):35-48. 10.30581/jkcmm.2020.15.1.35
|
|
|||||||||||||||||||||||||||||||||
|
|||||
PDF Links
Full text via DOI
PubReader
Download Citation 
Print 
